Device: Desktop
Opening
a new frontier
in pharmacology
Opening
a new frontier
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Latest News
Latest News
The European Commission grants €6 million to the ICOD project for the development of AEF0217 (Aelis Farma) to treat cognitive deficits in Down syndrome
April 2021
+
Aelis Farma announces good results from its first administration in humans for AEF0217, its first drug candidate for the treatment of cognitive disorders in ...
November 2021
+